Monthly Archives: May 2016

European Urainium Changes Names to Azarga Metals

White Rock, BC / ACCESSWIRE / May 30, 2016 / European Uranium Resources, Ltd. (TSX-V:EUU) (the “Company”) is pleased to announce that further to its news release dated March 1, 2016, the Company has taken the final steps to consolidate its shares on a 10 old for 1 new basis and has changed its name to Azarga Metals Corp. The common shares of the Company will commence trading on a consolidated basis at open of market on Tuesday, May 31, 2016 as Azarga Metals Corp. under the trading symbol AZR.

Registered shareholders will be mailed a letter of transmittal instructing them how to exchange their shares.

On May 31, 2016, the Company will concurrently close, on a post-consolidated basis, the acquisition of 60% of the Unkur Copper-Silver Project in eastern Russia, the concurrent private placement raising $2 million and finally the settlement of related party debt (the “Transactions”) all as announced on March 1, 2016. Alexander Molyneux and Vladimir Pakhomov will join Michael Hopley and Dorian (Dusty) Nicol on the Board of the Company to fill the vacancies created by the agreed upon resignations of David Montgomery and David (Sam) Hutchins.

The following table sets out the share structure for the Company after all of the Transactions are completed.

		Number of common shares
Existing common shares on issue		65,942,653

Common shares post 10:1 consolidation		6,594,265
New shares to be issued May 31, 2016:
– Unkur Acquisition (to Selling Shareholders)		15,776,181
– Private Placement		20,000,000
– Finder’s fee on private placement		32,500
– Settlement of existing EUU debts		577,572
Total post-transactions common shares		42,980,518

All of the common shares to be issued May 31, 2016, will be subject to a hold period in Canada expiring on October 1, 2016 and the shares to be issued to the Selling Shareholders will be subject to an additional twenty months so that the 15,776,181 shares will not be able to be traded until May 31, 2018 at the earliest.

EUROPEAN URANIUM RESOURCES LTD.

“Dusty Nicol”

Dorian L. (Dusty) Nicol, President and CEO

For further information please contact:
Doris Meyer
(604) 536-2711 ext 6
www.euresources.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement:
This news release contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur and include, without limitation, statements regarding the Company’s plans with respect to statements about the Company’s ability to fund and execute the proven ore processing business model outlined in this news release. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Source: European Uranium Resources, Ltd.

ReleaseID: 440539

Altiplano Announces Increase in Proposed Private Placement

EDMONTON, ALBERTA /ACCESSWIRE / May 30, 2016 / Altiplano Minerals Ltd. (TSXV: APN) (“APN” or the “Company“) further to the Company’s press release dated May 3, 2016, APN announces that it has increased the non-brokered private placement (the “Offering“) by 1.0 million units (the “Units“). The total Offering has therefore increased from 5.0 million units to 6.0 million units at C$0.10 per Unit to raise C$600,000 in gross proceeds. Each Unit will consist of one (1) common share and one-half (½) of a non-transferable share purchase warrant (the “Warrants“) of the Company. Each whole Warrant will be exercisable to acquire one (1) additional common share at $0.15 per share for a period of one year from the closing date of the Offering. The Company may pay cash finder’s fees raised in connection with the financing to arm’s length finders in accordance with the policies of the TSX Venture Exchange.

Completion of the Offering is subject to the delivery of definitive subscription agreements and TSX Venture Exchange’s acceptance. All of the securities issued pursuant to this Offering will have a hold period expiring four months and a day after the closing date. The net proceeds of the Offering will be used primarily for the Company’s general working capital purposes.

About Altiplano Minerals Ltd.

Altiplano Minerals Ltd. (TSXV: APN) is a mineral exploration company focused on evaluating and acquiring projects with significant potential for advancement from discovery through to production, in Canada and abroad. Management has a substantial record of success in capitalizing opportunity, overcoming challenges and building shareholder value. Additional information concerning Altiplano can be found on its website at www.altiplanominerals.com.

ON BEHALF OF THE BOARD
/s/ “John Williamson”
President and CEO
Tel: (780) 437-6624

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the (TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address exploration drilling, exploitation activities and events or developments that the Company expects are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continuity of mineralization, uncertainties related to the ability to obtain necessary permits, licenses and title and delays due to third party opposition, changes in government policies regarding mining and natural resource exploration and exploitation, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. For more information on the Company, investors should review the Company’s continuous disclosure filings that are available at www.sedar.com.

Source: Altiplano Minerals Ltd.

ReleaseID: 440540

Dark Clouds Over Clayton Valley and Green Lights for Belmont’s Kibby Basin Project

ZURICH, SWITZERLAND /
ACCESSWIRE / May 30, 2016 / Today, Rockstone Research published an update on Belmont Resources Inc. (TSX.V: BEA) as the company announced earlier today to have received exchange approval for acquiring 100% of the Kibby Basin Property, located 65 km north of the Clayton Valley in Nevada, USA. According to the newly filed NI43-101 Technical Report, the property has potential to host lithium-bearing brines in a geological setting similar to the continental brine model ascribed to the Clayton Valley.

As Albermarle Corp. has filed an official protest with the Nevada Division of Water Resources (NDWR) against any further granting of water rights in the “overapproriated” Clayton Valley, other basins in Nevada prospective for lithium brines – such as Kibby Basin – may experience an increased investor’s interest in the near future.

Rockstone expects Belmont to start exploration at Kibby Basin shortly, potentially creating vast shareholder value in case commercial grades of lithium-bearing brines can be identified on its property.

The full report can be accessed with the following links:

English (PDF): http://rockstone-research.com/images/PDF/Belmont2en.pdf

English (web version):http://rockstone-research.com/index.php/en/research-reports/1123-Dark-clouds-over-Clayton-Valley-and-green-lights-for-Belmonts-Kibby-Basin-Project

German (PDF): http://rockstone-research.com/images/PDF/Belmont2de.pdf

Disclaimer: Please read
the full disclaimer within the full research report as a PDF as fundamental
risks and conflicts of interest exist.

Source: Rockstone Research

ReleaseID: 440537

IMAGING DYNAMICS COMPANY LTD. Reports First Quarter 2016 Results

Untitled Document

Calgary, Alberta / ACCESSWIRE / May 30, 2016 / Imaging Dynamics Company Ltd. (“IDC” or the “Company”) (TSXV: IDL) reports its financial results for the first quarter ended March 31, 2016.

2016 First Quarter Highlights

The first quarter of 2016 saw IDC begin to execute its new strategy to renew the Company and its products as follows:

Investments in people and Research and Development were made.
The Shanghai Research and Development subsidiary and the new Beijing Sales and Marketing subsidiary began full operations.
IDC entered into a new lease to move its Head Office to a new location in Calgary which will have updated facilities to house its sales and research operations with the move to be completed by the end of the 2nd quarter 2016.
IDC completed its second private placement in the form of a convertible debenture offering on January 22, 2016 to help ensure it has sufficient resources to execute on the new strategy.

Operating Results

Gross revenues for the first quarter were $836,432 compared to $485,385 for the prior year quarter, which is an increase of 72% percent over last year. Most of the increase is attributed to increased activity in the Asia-Pacific region and new product sales. Gross margins were $244,194 or 29% vs 55% for the prior year quarter. Margins in 2015 were unusually high as IDC sold several parts with low inventory costs due to previous write-downs.

Operating costs (sales and marketing, general and administrative, production and manufacturing, and research and development) were up by 150 percent to $1,242,570 from $476,441 as compared to the prior year. The increase reflects the investment in people and is directly attributed to establishing operations in Calgary, Shanghai, and Beijing. Included in this total is research and development costs which increased by 571%. The Company is focusing on building and investing in its new strategic direction to address its goals of achieving further product development, diversification and operating efficiencies to build on its global brand recognition.

Financing costs increased to $213,191 from $14,794 in the prior period due to IDC`s commitments arising from the convertible debentures.

For the reasons mentioned above, the net loss for the quarter ended March 31, 2016 was $1,295,582 compared to a net loss of $288,968 for the same period of 2015.

“In the first quarter of 2016, IDC began making tangible investments in its future. We are pleased with our efforts so far and expect to see the first positive results of the hard work of our people in the second half of 2016,” said Mr. Yucheng Zhou, IDC’s CEO and Chairman.

A conference call to discuss the quarters results is not planned at this time, but the Company will hold its Annual General Meeting in Calgary, Alberta on Monday, July 18, 2016.

About Imaging Dynamics Company (IDC):

IDC is a global medical imaging technology and device provider and innovative force in the high growth field of digital radiography (DR) technology.

The Company has over 4,000 installations in 50 countries of its proprietary, award winning direct capture DR technology, which replaces conventional film-based diagnostic imaging and provides a cost-effective solution for medical facilities of all sizes to provide high quality diagnostic X-ray images and improve the level of healthcare for their patients.

Throughout its history, IDC has been recognized by multiple industry organizations and research analysts such as Frost & Sullivan and Deloitte Technology for its dedication to innovation, global market growth, and customer focused value proposition.

The Company has its corporate office in Calgary, Canada, a sales and marketing office in Beijing, China, and also an operations and research and development centres in Calgary, Canada and Shanghai, China.

Visit the IDC web site: www.imagingdynamics.com

For more information, please contact:
Mr. Xin (“Andy”) Cheng
Assistant Corporate Secretary
1.403.251.9939 Office
1.866.975.6737 Toll Free
chengxin@imagingdynamics.com

Statements in this release which describe IDC’s intentions, expectations or predictions, or which relate to matters that are not historical facts are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties which may cause the actual results, performances or achievements of IDC to be materially different from any future results, performances or achievements expressed in or implied by such forward-looking statements. IDC may update or revise any forward-looking statements, whether as a result of new information, future events or changing market and business conditions. Known and unknown risks and uncertainties include: IDC’s ability to manufacture its products with a sufficient level of quality and in volumes which satisfy market demand; the ability of IDC to establish direct and indirect sales channels; the ability of IDC to establish industry partnerships; IDC’s ability to attract and retain key personnel; the strength and breadth of IDC’s patents; and other factors relating to general economic conditions, specific industry conditions and IDC’s particular situation.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Source: Imaging Dynamics Company

ReleaseID: 440538

Luxury Panache Promotes Versatile Uses of The Culinary Kitchen Food Torch

Luxury Panache announces the arrival of fresh new stock of Culinary Kitchen Torches at Amazon.com. This versatile kitchen torch can not only be used for preparing delightful crème brulee but is multifunctional in use.

Southampton, UK – May 30, 2016 /PressCable/ —

Luxury Panache is pleased that the new order of the culinary kitchen torch has arrived at Amazon in time for the summer season with the versatility of outside use. It is particularly useful for lighting the BBQ with the piezzo ignition, safe locking device, flame guard for extra protection and an easy on/off switch.

Besides lighting the BBQ, it can be used to torch any meat and roast vegetables giving the meal outside on a summer’s evening that extra special touch. This gives the opportunity for home cooks to take food preparation to the next level whilst entertaining in the outdoors. The versatile kitchen torch can be used beforehand to prepare a delicious crème brulee or brown a mouth watering meringue on top of a tart and toast a bread crumb topping for the salad. The applications are endless and only limited by one’s imagination in preparing both sweet and savoury dishes.

The multifunctional kitchen torch can also be used outside for cleaning the surface of metals and the air flow valve easily controls the temperature and the torch has been designed to fit the hand comfortably thus enabling it to be used for longer period of time.

The kitchen torch is also ideal for jewellery making with the high heat capacity and adjustable flame and plumbing with the flame guard for extra protection and safe locking device to prevent accidental use.

After heavy use, it can easily be refilled from the gas filling hole on the bottom with butane gas readily available from most local hardware stores. The kitchen torch is manufactured to the same high standard that customers expect from Luxury Panache’s quality kitchen tools in eco friendly components which are all disposable.

Luxury Panache’s culinary kitchen food torch has a 100% money back guarantee on all sales and is available exclusively at Amazon.com

For more information about us, please visit http://www.luxury-panache.com/#!The-many-ways-to-use-the-Luxury-Panache-culinary-torch/c1deo/56ec5b5b0cf203534b123949

Contact Info:
Name: Joan Houghton
Organization: Luxury Panache
Phone: 44 7867434852

Release ID: 116881

Ziplocal Inc. Announces the Appointment of Interim Chief Executive Officer and Interim Chief Financial Officer

Untitled Document

TORONTO, ONTARIO / ACCESSWIRE / May 30, 2016 / ZipLocal Inc. (NEX:ZIP.H) (“ZipLocal”) announces that the Board of Directors has approved the appointment of Raj Ravindran, CFA, MBA, Ph.D as Interim Chief Executive Officer (CEO) and Interim Chief Financial Officer (CFO). Both positions were vacant as a result of the resignations of Paul Van Damme as CFO and Director, and Kevin Dane as CEO and Director.

About ZipLocal Inc.
ZipLocal Inc. is listed on the NEX Board of the TSX Venture Exchange.

Contact:
ZipLocal Inc.
Laurence Ezer
(416) 574-9824
laurence@wadeco.ca

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: Ziplocal Inc.

ReleaseID: 440535

Xarelto Lawsuit Plaintiffs Note Defective Device Used In Clinical Trials Of Drug

May 30, 2016 – – TheProductLawyers.com reports on a 3-year long clinical trial that the makers of Xarelto hired Duke University to undertake for Xarelto, a then newly developed blood-thinning drug. Xarelto trials began in 2006 and reviewed the blood-thinning effects in a sample of 14,000 patients of a Xarelto compared to warfarin, a more traditional blood thinner. There is currently an investigation underway about this particular clinical trial. Many are questioning the use of a defective testing device during the trials that would have influenced the results that ultimately indicated that Xarelto was more effective since the defective device in question allegedly gave patients the wrong dosage of warfarin.

A recent Business Insider article has stated that Xarelto has become the focus of more than 5,000 lawsuits, as well as 500 allegations of fatalities. Plaintiffs in these cases and others now question whether the data would have made a difference in assessing the safety of the drug.

It is also being reported that Duke Researchers may have failed to provide all the requisite data of the trial for publishing in the New England Journal of Medicine (NEJM). As a result, the manufacturers, Janssen Pharmaceuticals, a subsidiary of the Johnson and Johnson Corporation, and Bayer AG, are being accused of intentional deception by not giving the NEJM all the necessary data for its assessment, which most likely led to FDA approval of the drug and its subsequent release on the market.

Lawyers in a legal briefing recently filed allege that the makers of Xarelto did not say anything after noticing Duke’s omitted data related to a recalled blood testing device used in the trial, as well as remaining quiet as the information about the drug was sent to US and European regulators. By doing so, Janssen and Bayer in effect misled the NEJM and the many readers who rely on the journal’s information, as well at the patients who would eventually use the drug.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010282

Investigation Into Clinical Trials Underway As Xarelto Lawsuit Filings Increase

May 30, 2016 – – TheProductLawyers.com reports on the initial excitement over the release of Xarelto, a new-generation blood-thinning drug. The U.S. Food and Drug Administration (FDA) approved the drug in 2011 to treat knee and hip replacement surgery patients, as well as those suffering from a number of medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation, a common heart condition. Xarelto was unlike other blood-thinning drugs before it because it allowed for more freedoms to patients taking it.

Since its release, however, the drug has become the focus of controversy on numerous fronts. First and foremost, over 3,400 lawsuits have been filed against the makers of the drug, Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation, and Bayer AG. This multitude of complaints has been consolidated into two primary groups. In Philadelphia, PA, the Court of Common Pleas consolidated over 600 cases in a mass tort program. In Louisiana, another group in excess of 2,800 federal cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) and given number 2592. The multidistrict litigation (MDL) has been placed under the oversight of the Honorable Judge Eldon Fallon. The cases were consolidated in both of these instances due to similar allegations over the dangerous risks of the drug and the fact that the defendants were the same in all of the individual lawsuits filed.

Additionally, the controversy surrounding the drug has been compounded by two other factors. The first are the investigations currently underway related to the drug’s clinical trials and a medical device that has been alleged to be potentially defective. The other issue fanning the flames of discontent with Xarelto is the FDA’s issuance of two black box warnings for the drug. These warnings are very severe and the harshest warnings that can be given to a product that could ultimately result in the product’s complete removal from the consumer market.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010281

As Xarelto Lawsuit Filing Continue To Increase New Investigation Of Clinical Trials Takes Place

May 30, 2016 – – TheProductLawyers.com reports on the increasing number of lawsuits filed against the makers of Xarelto, Janssen Pharmaceuticals, a subdivision of the Johnson and Johnson Corporation, and Bayer AG. To date, there have been over 3,400 lawsuits filed since the drug’s approval by the U.S. Food and Drug Administration (FDA) in 2011 and have uniformly and consistently named Janssen and Bayer as defendants.

Given the breadth of the number of cases and the commonalities among them, the cases were consolidated into two primary groups. The biggest is a multidistrict litigation (MDL) numbering over 2,800 federally-filed cases that were consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML). The JPML assigned jurisdiction over these cases to the Honorable Judge Eldon Fallon in the Eastern District of Louisiana and has been given number 2592. The second group is one that numbers in excess of 600 cases and is a mass tort program in Philadelphia, PA that was grouped together by the Court of Common Pleas.

When Xarelto was released on the market in 2011 it was a very highly rated, new-generation blood thinner drug with consumers since it accorded them more freedoms than the preceding types of blood-thinning drugs. It was FDA approved to treat patients recovering from hip or knee replacement surgeries as well as those suffering from deep vein thrombosis, pulmonary embolism, and a common heart condition known as atrial fibrillation. However, since that time, and in addition to the lawsuits filed, it has become the focus a number of investigations related to the clinical trials as well as a defective medical device.

Another development and probably one of the most ominous and telling indication of the future of Xarelto are the two “black box” warnings the drug has received from the FDA. These warnings are the harshest and most severe warnings that can be issued to a product prior to its potential removal from the consumer market.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60010280

Medical Animation Market Rising at 20.8% CAGR to Reach $301.3 Million by 2021

Medical animation market is to reach USD 301.3 million by 2021 growing at a CAGR of 20.8% during the forecast period of 2016 to 2021 and dominated by the North America with the largest share of the global medical animation.

Pune, India – May 30, 2016 /MarketersMedia/ —

The medical animation market is poised to reach USD 301.3 million by 2021 from USD 117.3 million in 2016, growing at a CAGR of 20.8% during the forecast period of 2016 to 2021. The 3D animation segment is expected to account for the largest share of the medical animation market, by type, in 2016. 3D animation provides viewers a greater sense of perspective, and enables clear understanding of the key concepts in a forensic case; this is contributing to the large share of this segment.

Complete report on global medical animation market spread across 160 pages, profiling 12 companies and supported with 79 tables and 73 figures is now available at http://www.reportsnreports.com/reports/567883-medical-animation-market-by-type-3d-2d-4d-therapeutic-area-oncology-cosmeceutical-plastic-surgery-application-drug-moa-patient-education-end-user-medical-device-manufacturers-hospitals-clinics-forecast-to-2021.html .

Medical animation is an educational video or movie created using 3D motion graphics to explain the mechanism of action (MoA) of a medical device, biomedical technology, pharmaceutical drug, or an anatomical or biological process. Animations are used in the medical and pharmaceutical sectors for educational purposes, demonstrations, simulation of surgeries, and analysis and comparative evaluation of treatment.

The drug mechanism of action (MoA) and approvals segment is expected to account for the largest share of the medical animation market, by application, in 2016. The rising adoption of medical animation by pharmaceutical companies for showcasing the MoA of drugs as well as for the marketing, promotions, and approvals of products is driving growth in this market segment.

The oncology segment is expected to account for the largest share of the global medical animation market, by therapeutic area, in 2016. This is attributed to the increasing awareness amongst healthcare professionals on various diseases, injuries, and defects; and rising adoption among academic institutes to explain and provide instructions to students on physiotherapy and pre- and post-orthopedic procedures. The life science companies segment is estimated to account for the largest share of the medical animation market, by end user, in 2016. Life sciences companies mainly use medical animation as a marketing tool to promote new drugs and product offerings.

North America is expected to account for the largest share of the global medical animation market in 2016, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of the North American region can be attributed to the presence of major pharmaceutical companies, increased healthcare spending, presence of top market players, increasing number of surgeries in the U.S., and growing medical devices industry in Canada. The Asia-Pacific region is expected to witness the highest growth rate in the forecast period, mainly due to the growing pharmaceutical industry, growing number of medical institutes in India, lucrative medical devices industry in China, and entry of local players and low cost of medical animation in India.

Prominent players in the global medical animation market include Infuse Medical (U.S.), Hybrid Medical Animation, Inc. (U.S.), Ghost Productions, Inc. (U.S.), Scientific Animations, Inc. (U.S.), INVIVO Communications, Inc. (Canada), Random42 Scientific Communication (U.K.), Radius Digital Science (U.S.), Nucleus Medical Media, Inc. (U.S.), AXS Studio, Inc. (Canada), Visible Body (U.S.), Elara Systems, Inc. (U.S.), Animated Biomedical Productions (Australia), XVIVO Scientific Animation (U.S.), Blausen Medical Communications, Inc. (U.S.), Trinsic Medical Animation, LLC. (U.S.), Viscira (U.S.), Understand.com (U.S.) and Med movie, Inc. (U.S.). Ask for the discounted copy of the report of Medical Animation Market by Type (3D, 2D, 4D), Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), Application (Drug MoA, Patient Education), End User (Medical Device Manufacturers, Hospitals/ Clinics) – Forecast to 2021 research report at http://www.reportsnreports.com/contacts/discount.aspx?name=567883 .

The medical animation market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (agreements, partnerships, joint ventures, collaborations, expansions, new product launches, and acquisition) to increase their market shares and establish a stronger foothold in the global market.

On a related note, another research on Medical Image Analysis Software Market Global Forecasts to 2020 says, the medical image analysis software market is expected to reach USD 3,135.3 Million by 2020 from USD 2,143.7 Million in 2015, at a CAGR of 7.9% from 2015 to 2020. North America is expected to dominate the market in 2015, with the U.S. accounting for a major share of this regional segment. The research is based on by Type, Image (2D, 3D, 4D), Modality, Application and End User.

Companies like AGFA Healthcare, Aquilab, Carestream Health, Inc., Esaote S.p.A, GE Healthcare, Merge Healthcare, Inc., MIM Software Inc., Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems Corporation have been profiled in this 312 pages research report available at http://www.reportsnreports.com/reports/203752-medical-image-analysis-software-market-integrated-standalone-market-technologies-x-ray-ct-ultrasound-mri-spect-pet-image-type-2d-3d-4d-indications-neurology-cardiology-radiology-global-trends-opportunities-forecasts-till-2017.html .

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

For more information about us, please visit http://www.reportsnreports.com

Contact Info:
Name: Ritesh Tiwari
Organization: Reports and Reports
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar
Phone: + 1 888 391 5441

Source: http://marketersmedia.com/medical-animation-market-rising-at-20-8-cagr-to-reach-301-3-million-by-2021/117274

Release ID: 117274